3D Medicines Inc. (01244) reported no movements in share capital for the month ended 31 March 2026, according to its latest Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 02 April 2026.

Authorised/Registered Share Capital • The authorised share capital remained at 500.00 million ordinary shares with a par value of HKD 0.001, equivalent to HKD 500,000. No changes were recorded during the month.

Issued Share Capital and Treasury Shares • Issued shares stood unchanged at 258.18 million. • The company held zero treasury shares, and no repurchases or cancellations occurred.

Public Float Status • 3D Medicines confirmed compliance with the Main Board’s minimum 25% public-float requirement as of 31 March 2026.

Equity Incentive Arrangements • The Share Option Scheme, approved on 26 June 2023, carried 12.80 million outstanding options at month-end. • No options were exercised, and no new shares were issued under the scheme during March; funds raised from option exercises were therefore HKD 0.

Other Securities • The company reported no warrants, convertibles, or other share-issuance arrangements in force, and no additional share movements occurred.

Governance Confirmation • The filing was submitted by Director Gong Zhaolong, who confirmed compliance with all applicable listing rules, legal requirements, and procedural safeguards regarding any potential securities activities during the period.